Moxifloxacin HCL

The eye presents unique opportunities and challenges for the delivery of pharmaceutical dosage forms. Ocular inserts of Moxifloxacin HCl were prepared with the objective of reducing frequency of administration, controlled release and greater therapeutic effect. Moxifloxacin HCl a broad spectrum fourth generation fluroquinolone used in the treatment of conjunctivitis, keratitis, kerato-conjunctivitis etc. In the present wok reservoir type of ocular inserts formulated by sandwiching poly vinyl alcohol containing Moxifloxacin HCl in between two rate controlling membranes of ethyl cellulose and PVP-K30. The reservoir types of ocular inserts containing Moxifloxacin HCl were formulated by film casting technique using PVA as drug reservoir polymer and EC: PVP-K30 as a rate controlling material. In vitro drug release revealed that the optimized (FM6) formulation showed a controlled release. In vivo studies showed a release of 97.67% over a period of 5 days with high correlation coefficient  of  In vitro-In vivo release studies. In the present study the ocular inserts of Moxifloxacin HCl (FM6) provided desired drug release for 5 days and remained stable.